Cyrtominetin is an α-hemolysin inhibitor that works by directly binding to α-hemolysin and altering the conformation of its critical "Loop" region, subsequently inhibiting its lytic activity through a novel mechanism. This characteristic positions Cyrtominetin as a potential therapeutic agent against α-HL-mediated pathogenesis.